Xilio Therapeutics, Inc.
XLOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The $49.8M market capitalization puts XLO squarely in micro-cap range for its industry. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Market Cap
$49.8M
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
-13.05
EPS (TTM)
$-0.60
EPS (Fwd)
$-0.58
ROE
-55.0%
ROA
-13.6%
Cash
$136.0M
Total Debt
$6.3M
Free CF
-$37.6M
52W Change
-34.9%
Annual Financials
Cash vs Debt
Where XLO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XLO finished 4.03% below its 150-day moving average ($8.68) and 2.69% below its 200-day moving average ($8.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XLO overbought or oversold?
At the October 20, 2026 close, XLO's RSI(14) was 34.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Xilio Therapeutics, Inc. holds $136.0M in cash against $6.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$37.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -55.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Xilio Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Xilio Therapeutics, Inc. and its sector.